Navigation Links
DARA Announces Information in Compliance with NASDAQ Rules
Date:4/7/2008

RALEIGH, N.C., April 7, 2008 /PRNewswire-FirstCall/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today that the audit report accompanying the financial statements for the fiscal year ended December 31, 2007, as included in the Company's Annual Report on 10-K filed on March 31, 2008, contained a going concern qualification. NASDAQ Marketplace Rule 4350(b)(1)(B) requires that a public announcement be made regarding the receipt of an audit opinion that contains a going concern qualification.

In making the announcement, John C. Thomas, Jr., Chief Financial Officer, noted, "Given the financials for the year ended December 31, 2007 reflect Point Therapeutics' operating results and financial position prior to the merger with DARA BioSciences, the going concern qualification was expected. The merger with DARA BioSciences occurred on February 12, 2008 and the first reported results of the merged entity will be on Form 10-Q for the quarter ending March 31, 2008. With that said, it is also important to note that DARA has previously stated that it does intend to seek additional capital during the coming year."

About DARA BioSciences, Inc.

DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, and dermatological disorders.

DARA trades on the NASDAQ Global Market under the ticker symbol "DARA".

For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com.

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors include risks and uncertainties relating to the company's ability to develop and bring new products to market as anticipated, the current regulatory environment in which the company develops and sells its products, the market acceptance of those products, dependence on partners, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property, the intellectual property of others, the company's ability to raise capital, and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission. Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.


'/>"/>
SOURCE DARA BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Journey Lite of Thousand Oaks Announces Special Spring Price Discount In Response to Effects of Softening Economy on Patients Pocketbooks
2. VA Announces SGLI and VGLI Premium Reductions
3. London Luxury LLC Announces Exclusive Partnership with Cupron, Inc., to Develop Innovative Copper-Infused Bed and Bath Products
4. Boston Scientific Announces Appointment of Timothy Pratt as General Counsel
5. Accuri Cytometers Announces Commercial Launch of Revolutionary Accuri C6 Flow Cytometer(TM) System
6. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
7. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index (As Revised)
8. Smart Balance Announces Sales Organization Appointments
9. Global Action Board of Directors Announces Addition of Newest Member, Robert Hernreich
10. NTMir Announces First International Research Grant for Genome Sequencing
11. Dialysis Corporation of America Announces the Development of a New Facility in Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... August 18, 2017 — ... advocating for active, healthy lifestyles and highlighting the importance of proactive eye and ... impairments and shares the latest innovations in hearing aid technology. , According ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Dawn ... is inaugurating a new charity drive to generate community support for efforts to educate ... into cures and treatments for all types of cancer. , Each day in ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, ... communities in east Texas, is launching a regional charity effort to provide publicity ... 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... planning firm that serves residential and commercial clients in the greater Houston region, ... raise community support for the fight against cancer. , Founded by Tony and ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over ... in bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for ... aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
(Date:8/7/2017)... Aug. 7, 2017  Endo International plc (NASDAQ: ... to resolve virtually all known U.S. mesh product liability ... resolve the known remaining U.S. claims at reasonable values. ... in the fourth quarter of 2017 and continuing through ... second quarter 2017 results, the Company intends to increase ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology: